Medical Genomics Laboratory Officially Opened in the Presence of Berlins Governing Mayor Wowereit
The building is named after the Russian geneticist Nikolai
Wladimirovich Timoféeff-Ressovsky*, who worked at the Kaiser Wilhelm Institute
for Brain Research in Berlin-Buch from 1930 to 1945. He is considered to be one
of the founders of molecular genetics along with Max Delbrück, after whom the
MDC was named.
Prior to the symbolic handing over of the keys to the
Scientific Directors of MDC and FMP, the sculpture of Timoféeff-Ressovsky,
created by the Berlin sculptor Stefan Kaehne in 2006, was unveiled in front of
the building. During the festivities, the MDC and the FMP also celebrated the
75th anniversary of medical-biological research in Berlin-Buch. The Kaiser
Wilhelm Institute in Berlin-Buch was officially opened on June 2, 1931 in the
presence of Max Planck.
Prof. Walter Birchmeier, the MDC’s Scientific Director,
honoured the huge contributions of the Federal Government, the Land of Berlin,
and the European Union made to for the Berlin-Buch Campus. “They have invested
into this Campus about 237 Million Euros”, he pointed out. “This has made it
possible to transform this Campus into a highly modern, internationally
competitive research place, as we can see today with the new Laboratory for
Medical Genome Research”.
“The Campus has an excellent basis to combine the
unravelling of the origin of disease with the development of new therapeutical
concepts”, Prof. Walter Rosenthal, Director of FMP pointed out. Contributing to
this concept is the new laboratory building. He thanked the architects from the
office (Architekturbüro) Volker Staab and continued: “The Timoféeff-Ressovsky
Building is perhaps the most attractive one on the campus – the highlight of
all of the construction that has been going on during the past 15 years and
which has made this campus what it is today: a modern, interational research
campus with an excellent infrastructure.”
The keynote speeches were held by the neurobiologist Prof.
Thomas Jentsch, director of the Institute for Molecular Neuropathobiology
Hamburg (HMNH), who was recently appointed to a W3 professorship at Charité - Universitätsmedizin Berlin in
cooperation with the FMP, and the bioinformatician Prof. Nikolaus Rajewsky,
formerly of New York University (New York, USA), likewise appointed to a W3
professorship at MDC. Both will have their laboratories in the new building.
Prof. Jentsch, whose research group is equally funded by
the FMP and the MDC, spoke on “Function explained by dysfunction: Diseases
provide insight into the role of ion
transport”. His research in this area has contributed to our understanding as
to how different diseases are caused and how they develop. Prof. Rajewsky gave
a lecture on “New treatment options? Tiny human genes regulate thousands of
target genes“. He developed a high throughput method identifying the sites in
the genome to which very small RNA molecules bind and ultimately regulate the
production of proteins.
The four-story genomics research center has approximately
3,200 m² of floor space. After two years of construction, it was completed this
year. Located within the building is the Gene Mapping Center, which the MDC
founded several years ago within the framework of the German Human Genome
Project with funds of the German Research Ministry. In the special laboratory,
which has state-of-the-art technical equipment, scientists identify genes that
are involved in the development of diseases by means of high-throughput
procedures. This research is integrated into the National Genome Research
Network 2 (NGFN2). It is closely connected with MDC’s proteome research and is
of great significance for linking clinical and basic research.
Also located within the new building is the “Protein
Structure Factory” of the German Human Genome Project (
normal'>DHGP
) and of Berlin structural biologists, in which the MDC and the
FMP are also engaged. The project is aimed at analyzing the spatial structure
of proteins using high-throughput methods. In addition, the FMP runs its
“Academic Screening Unit” in the building. Here, in a high throughput
procedure, small molecules are identified which bind to proteins and have a
biological effect. These small molecules both
represent important tools for research and serve as prototypes for new types of
drugs as well. The work of the “Screening Unit” is supplemented by the FMP
research group “Medical Chemistry”.
Furthermore, the MDC and Charité are planning to create an
“Experimental and Clinical Research Center” (ECRC) on Campus Berlin-Buch. The
aim of all of these research activities is to speed the process of turning
scientific insights into medical treatments for patients.
The MDC was founded in Berlin-Buch in 1992. Since that
time, it has developed a future-oriented concept that enables research on an
array of clinical disorders such as cancer, cardiovascular diseases, and
diseases of the brain within the framework of molecular medicine. The MDC’s aim
is to understand the origins of these complex diseases and their progression by
studying the relevant genes and gene products. MDC scientists work closely with
oncologists and cardiologists of the nearby research hospitals of the Charité within the Helios Klinikum
Berlin. MDC is funded by the Federal Government of Germany (90 per cent) and by
the State of Berlin (10 per cent) and is a member of the Helmholtz Association.
The FMP, also founded in 1992, is equally funded by the
State of Berlin (50 per cent) and the Federal Government of Germany (50 per cent).
In late 2000, the FMP moved from Berlin-Friedrichsfelde to Campus Berlin-Buch.
The FMP’s core activity is basic research for drug development. Its primary aim
is to elucidate cellular regulation processes and to show how they can be
influenced pharmacologically at the molecular level. To achieve this purpose,
the institute researches the structure, function, and interactions of proteins.
One thematic priority is the identification of small molecules that bind to
proteins and influence their function. These molecules could potentially serve
as new substances for drugs or as tools for research. The close linkage of
biology and chemistry is characteristic for the research of the institute. The
FMP is a member of the Leibniz Association.
Leibniz-Institut für Molekulare Pharmakologie (FMP) im
Forschungsverbund Berlin
Dr. Björn Maul
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone:
0049/30/94 79 31 02
Fax:
0049/30/94 79 31 09
e-mail: maul@fmp-berlin.de
http://www.fmp-berlin.de
Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone.: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30
94 06 - 38 33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de